Presentation at American Society for Clinical Oncology Annual Meeting 2015
• Primary endpoint achieved with 38.6% (22/57) of late-stage melanoma patients achieved the irPFS endpoint
• Objective response rate of 28% (16/57) with eight patients achieving complete response
• Durable response persisting for at least 6 months in 21% of patients
• Activity in non-injected distant lesions, including lung and liver metastases
• One-year survival rate of 75.4% with median overall survival of 26 months
• Well tolerated in 57 patients - no grade 3 or 4 treatment-related adverse events
• Exciting results from biopsy study point to combination synergy with checkpoint inhibitors
• Teleconference scheduled for 16 June (US time)
2 June 2015, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) today provided positive final data from the Phase 2 CALM clinical trial of Viralytics’ lead drug candidate, CAVATAKTM, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015 in Chicago, IL. CAVATAK is an investigational novel cancer immunotherapy based on a proprietary bioselected common cold virus that has been shown to preferentially infect and attack cancer cells.
Dr Robert Andtbacka of the Huntsman Cancer Institute, University of Utah, and Lead Study Investigator, presented a poster detailing the final results from the Phase 2 CALM clinical trial, confirming earlier promising results in difficult-to-treat, late-stage melanoma patients.
Final Results
The final CALM results showed that 22 of the 57 (38.6%) patients achieved the irPFS endpoint, more than doubling the target of 10 of 54 evaluable patients reporting irPFS at six months after the first dose of CAVATAK.
Investigators also reported an overall response rate in 16 of 57 (28%) patients. Of these, eight patients achieved a complete response and disappearance of their total tumour burden and the other eight achieved a partial response being at least a 30% reduction in the tumour burden.
Durable responses, persisting for 6 months or more, were seen in 21% of patients. Notably, durable response was the FDA approved endpoint for the pivotal Phase 3 trial of Amgen’s oncolytic virus talimogene laherparepvec (T-VEC) which recently gained recommendation for approval from the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) with a 16.3% durable response rate.
Responses have been observed in patients who have progressed on other agents such as T-Vec and the checkpoint inhibitor ipilimumab.
Promising anti-cancer activity was demonstrated in non-injected distant cancers, including lung and liver metastases. A response rate of 37.5% was recorded in individual target lesions at these sites – suggestive of CAVATAK’s ability to trigger an anti-tumour immune response.
The one-year survival rate of 75% (43 of 57 patients) with a median overall survival of 26 months was achieved in a challenging population with advanced, intractable disease.
“These results mark CAVATAK as a new agent with significant promise in a range of settings, based on its performance in meeting the primary endpoint, its favourable tolerability profile, and its ability to produce durable responses. In addition, we are encouraged by initial interesting data showing that CAVATAK can reconstitute immune activity in the tumours of patients who have failed multiple other treatments -- suggesting a potential role in combination with other new immunotherapies," said Dr Andtbacka. “I look forward to a continuing role in studies which will help define the optimal clinical settings for CAVATAK, both in combination therapies and as a single agent.”
Extension (Biopsy) Study
Further results from the 13-patient CALM extension study were also reported. Biopsies were taken from melanoma lesions prior to and after CAVATAK administration. Results from the tumour tissue demonstrate that CAVATAK was able to induce anti-cancer immune activity. Specifically, there is evidence that CAVATAK induces key immune cells (such as cytotoxic T lymphocytes and PD-L1 expressing cells) to infiltrate the tumour tissue including into lesions of patients that have progressed on treatment ipilimumab, pembrolizumab or talimogene laherparepvec. Increases in the number of these cells are important signals of potential complementary activity in combination with important new immunotherapies such as checkpoint inhibitors .
Malcolm McColl, Viralytics Managing Director and CEO said “These results from our CALM trial represent a major milestone for Viralytics. We have demonstrated that CAVATAK has strong anti-cancer activity in late-stage patients, whilst being well tolerated. Durability of response and activity in non-injected sites are further indications of CAVATAK’s substantial potential.” He added “We are well funded and have excellent support from global thought-leading oncologists. With the excellent CALM results we have a solid platform for driving CAVATAK towards a commercial transaction.”
Poster Presentation
• Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma (Abstract #9030)
• Presenter: Dr Robert Andtbacka MD, CM, Associate Professor at the University of Utah-based Huntsman Cancer Institute and Lead Study Investigator for the CALM trial.
The poster is available on the Viralytics website.
Teleconference to Recap Poster Presentation
Investors and analysts are invited to join a teleconference on 16 June (US) / 17 June (Australia) in which Dr Andtbacka will step through the ASCO poster and field questions.
The teleconference will be recorded and a link provided on the Viralytics website. Information regarding exact timing and dial in details will be provided in a separate market release.
About Viralytics Ltd:
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics’ lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific ‘receptor’ proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics’ ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.
Help employers find you! Check out all the jobs and post your resume.
• Primary endpoint achieved with 38.6% (22/57) of late-stage melanoma patients achieved the irPFS endpoint
• Objective response rate of 28% (16/57) with eight patients achieving complete response
• Durable response persisting for at least 6 months in 21% of patients
• Activity in non-injected distant lesions, including lung and liver metastases
• One-year survival rate of 75.4% with median overall survival of 26 months
• Well tolerated in 57 patients - no grade 3 or 4 treatment-related adverse events
• Exciting results from biopsy study point to combination synergy with checkpoint inhibitors
• Teleconference scheduled for 16 June (US time)
2 June 2015, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) today provided positive final data from the Phase 2 CALM clinical trial of Viralytics’ lead drug candidate, CAVATAKTM, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015 in Chicago, IL. CAVATAK is an investigational novel cancer immunotherapy based on a proprietary bioselected common cold virus that has been shown to preferentially infect and attack cancer cells.
Dr Robert Andtbacka of the Huntsman Cancer Institute, University of Utah, and Lead Study Investigator, presented a poster detailing the final results from the Phase 2 CALM clinical trial, confirming earlier promising results in difficult-to-treat, late-stage melanoma patients.
Final Results
The final CALM results showed that 22 of the 57 (38.6%) patients achieved the irPFS endpoint, more than doubling the target of 10 of 54 evaluable patients reporting irPFS at six months after the first dose of CAVATAK.
Investigators also reported an overall response rate in 16 of 57 (28%) patients. Of these, eight patients achieved a complete response and disappearance of their total tumour burden and the other eight achieved a partial response being at least a 30% reduction in the tumour burden.
Durable responses, persisting for 6 months or more, were seen in 21% of patients. Notably, durable response was the FDA approved endpoint for the pivotal Phase 3 trial of Amgen’s oncolytic virus talimogene laherparepvec (T-VEC) which recently gained recommendation for approval from the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) with a 16.3% durable response rate.
Responses have been observed in patients who have progressed on other agents such as T-Vec and the checkpoint inhibitor ipilimumab.
Promising anti-cancer activity was demonstrated in non-injected distant cancers, including lung and liver metastases. A response rate of 37.5% was recorded in individual target lesions at these sites – suggestive of CAVATAK’s ability to trigger an anti-tumour immune response.
The one-year survival rate of 75% (43 of 57 patients) with a median overall survival of 26 months was achieved in a challenging population with advanced, intractable disease.
“These results mark CAVATAK as a new agent with significant promise in a range of settings, based on its performance in meeting the primary endpoint, its favourable tolerability profile, and its ability to produce durable responses. In addition, we are encouraged by initial interesting data showing that CAVATAK can reconstitute immune activity in the tumours of patients who have failed multiple other treatments -- suggesting a potential role in combination with other new immunotherapies," said Dr Andtbacka. “I look forward to a continuing role in studies which will help define the optimal clinical settings for CAVATAK, both in combination therapies and as a single agent.”
Extension (Biopsy) Study
Further results from the 13-patient CALM extension study were also reported. Biopsies were taken from melanoma lesions prior to and after CAVATAK administration. Results from the tumour tissue demonstrate that CAVATAK was able to induce anti-cancer immune activity. Specifically, there is evidence that CAVATAK induces key immune cells (such as cytotoxic T lymphocytes and PD-L1 expressing cells) to infiltrate the tumour tissue including into lesions of patients that have progressed on treatment ipilimumab, pembrolizumab or talimogene laherparepvec. Increases in the number of these cells are important signals of potential complementary activity in combination with important new immunotherapies such as checkpoint inhibitors .
Malcolm McColl, Viralytics Managing Director and CEO said “These results from our CALM trial represent a major milestone for Viralytics. We have demonstrated that CAVATAK has strong anti-cancer activity in late-stage patients, whilst being well tolerated. Durability of response and activity in non-injected sites are further indications of CAVATAK’s substantial potential.” He added “We are well funded and have excellent support from global thought-leading oncologists. With the excellent CALM results we have a solid platform for driving CAVATAK towards a commercial transaction.”
Poster Presentation
• Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma (Abstract #9030)
• Presenter: Dr Robert Andtbacka MD, CM, Associate Professor at the University of Utah-based Huntsman Cancer Institute and Lead Study Investigator for the CALM trial.
The poster is available on the Viralytics website.
Teleconference to Recap Poster Presentation
Investors and analysts are invited to join a teleconference on 16 June (US) / 17 June (Australia) in which Dr Andtbacka will step through the ASCO poster and field questions.
The teleconference will be recorded and a link provided on the Viralytics website. Information regarding exact timing and dial in details will be provided in a separate market release.
About Viralytics Ltd:
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics’ lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific ‘receptor’ proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics’ ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.
Help employers find you! Check out all the jobs and post your resume.
